Peripheral artery disease

Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow

Retrieved on: 
Wednesday, November 1, 2023
FDA, Peripheral artery disease, Artery, Education, Chin Na, Chronic limb threatening ischemia, Mortality, Vein, CLTI, Conference, Acquisition, Foot, Quality of life, Leg, Growth, Disease, Risk, The New England Journal of Medicine, Latham & Watkins, Hand, S.A, Safety, Amputation, Patient, VTE, BofA Securities, Pharmaceutical industry, Nursing, Retail

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it has entered into a definitive agreement to acquire LimFlow, S.A., a privately held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). Under the terms of the agreement, Inari will pay $250 million in cash at closing and LimFlow will be eligible to receive additional cash payments based on certain commercial and reimbursement milestones. The transaction is expected to close in the fourth quarter of 2023.

Key Points: 
  • Under the terms of the agreement, Inari will pay $250 million in cash at closing and LimFlow will be eligible to receive additional cash payments based on certain commercial and reimbursement milestones.
  • LimFlow has already trained and deployed an initial team of sales representatives in targeted U.S. markets who are executing the launch of the LimFlow therapy.
  • Inari anticipates continuing to expand this team as a focused, dedicated sales force separate from Inari’s existing VTE sales organization.
  • Inari plans to leverage these same capabilities to successfully commercialize the LimFlow System in the United States.

LimFlow Announces Agreement to Be Acquired by Inari Medical

Retrieved on: 
Wednesday, November 1, 2023
Cardiology, Radiology, Surgery, Health, FDA, Medical Devices, Clinical Trials, Other Health, Peripheral artery disease, Femoral vein, Chronic limb threatening ischemia, CLTI, MD, Acquisition, Sofinnova, Leg, Growth, The New England Journal of Medicine, Amputation, Transcatheter arterial chemoembolization, Pain, Patient, PAD, Wound healing, Pharmaceutical industry, Nursing

The LimFlow System is the first and only FDA-approved device for TADV and previously received Breakthrough Device Designation from the FDA.

Key Points: 
  • The LimFlow System is the first and only FDA-approved device for TADV and previously received Breakthrough Device Designation from the FDA.
  • "We are thrilled to join forces with Inari Medical, expanding the reach of our remarkable technology to bring renewed hope to patients who are currently suffering," said LimFlow CEO Dan Rose.
  • "Our heartfelt gratitude goes out to the exceptional LimFlow team, our dedicated clinical partners, and our investors who believed in our mission.
  • “The acquisition of LimFlow is closely aligned with our mission to address significant unmet patient needs and adds another highly differentiated growth platform into our portfolio,” said Drew Hykes, CEO of Inari.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform—and Appointment of Chief Operating Officer

Retrieved on: 
Monday, October 30, 2023
Cardiology, Medical Supplies, Surgery, Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Abbott, CIS, FDA, Peripheral artery disease, Physician, Libin Cardiovascular Institute, Terrebonne, JNJ, ABIOMED, Philips, CSI, Multimedia, Growth, Intersect ENT, Hip, Sales & Marketing Executives International, Physics, Intersection, DRS, Ankle, Calcium, Patient, Medtronic, Atherectomy, PAD, Pharmaceutical industry, Medical imaging, Management

View the full release here: https://www.businesswire.com/news/home/20231027207271/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231027207271/en/
    Cardio Flow announced the successful completion of its first commercial cases in leading medical centers across the U.S.
  • Michael Kallok, Ph.D., CEO of Cardio Flow, also announced the appointment of Scott Kraus as Chief Operating Officer.
  • Most recently, Scott served as Vice President of Sales & Marketing for Cardio Flow and was responsible for overseeing all commercial functions.
  • Most notably, he was part of the commercial team at CSI that launched the orbital atherectomy systems.

A new anticoagulant in Pharmascience Canada's portfolio this fall!

Retrieved on: 
Thursday, November 2, 2023
Ischemia, Stroke, CAD, Peripheral artery disease, THR, Mortality, Atrial fibrillation, Coronary artery disease, Pulmonary embolism, Anticoagulant, PE, DVT, Rivaroxaban, Myocardial infarction, ASA, Deep vein thrombosis, TKR, Tablet, Safety, Patient, PAD, VTE, Phosphorus, Pharmaceutical industry

MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.

Key Points: 
  • MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.
  • It helps prevent blood clots from forming by directly blocking the activity of a clotting factor called Factor-Xa.
  • "Pharmascience is proud and committed to serving Canadian patients through the local production of our medications!
  • mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada.

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Blood vessel, Patient, Angiography, Isabella Tree, Peripheral artery disease, PTA, De novo, Artery, Education, Incidence, DCB, Ioctl, BMI, AVF, CLTI, Kaplan–Meier estimator, Kidney disease, Research, HIV disease progression rates, RCT, Wound healing, BRS, Dialysis, Thrombosis, Clinical trial, Extremities, Risk, Dural arteriovenous fistula, Magnitude, Classification, VIVA, IVUS, Amputation, BTK, PAD, Wynn Las Vegas, Infection, Medical imaging, Pharmaceutical industry, Silviculture

Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
  • Results from Abbott's LIFE-BTK randomized clinical trial (RCT) demonstrate that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
  • In the LIFE-BTK trial, wound assessment was not a prespecified powered primary or secondary endpoint but rather a prespecified descriptive endpoint.
  • The trial offers the largest ischemic wound data set to date, collected systematically and adjudicated independently in a blinded fashion.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Atheroma, Peripheral artery disease, Diabetes, Pivotal trial, Ulcer, Transducer, Male, Disease, PAP, Buerger's test, Classification, The Unreconstructed M, IVUS, Amputation, Stent, PAD, PP, Thorpe tube flowmeter, TUS, Calf, Chin Na, Vein, Telephone, TASC, Bare, Vibrato, Life, SP, W. L. Gore & Associates, VIVA, Safety, Patient, Dyslipidemia, Blood vessel, Plaque, History, CLTI, Coronary artery disease, Perfusion, Restenosis, Research, Foot, Spur, Atherectomy, Șaeș, Artery, Education, DCB, Doppler effect, Dialysis, Hypertension, FP, Freedom, Wynn Las Vegas, Wound healing, Medical imaging, Pharmaceutical industry, Birth control, Surveying, Medtronic

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

The Inner Circle Acknowledges, Patrick Tamim as a Pinnacle Life Member for his contributions to the Vascular Surgery Field

Retrieved on: 
Wednesday, October 25, 2023
Emerald, Knowledge, Stroke, Peripheral artery disease, Artery, Education, Ageing, Council, National Council on Aging, Vein, Aortic aneurysm, American Board of Commissioners for Foreign Missions, American Board of Surgery, Varicose veins, PANAMA, Mentorship, Multimedia, ABS, Medical degree, Dialysis, Inner circle, Henry Ford Hospital, Surgeon, Methodist University, Southern Methodist University, Moyamoya disease, University, Blood, Society, Patient, Hartford Hospital, Dentistry, Nursing, Science, MD, Biology, Chemistry

PANAMA CITY, Fla., Oct. 25, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.

Key Points: 
  • PANAMA CITY, Fla., Oct. 25, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.
  • Dr. Tamim attended Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry.
  • He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut.
  • Among his many responsibilities and skills, the doctor provides treatment for carotid disease; aortic aneurysm; and peripheral artery disease surgery.

Massachusetts General Hospital Researchers and Prevencio Announce AI-driven HART® CVE Blood Test Accuracy for Patients with Coronary Chronic Total Occlusion

Retrieved on: 
Tuesday, October 24, 2023
Research, Technology, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Health, Science, Artificial Intelligence, Massachusetts General Hospital, Principal, Stroke, Peripheral artery disease, Harvard Medical School, Obesity, HART, MD, Diabetes, CVE, Artificial intelligence, Chronic kidney disease, Myocardial infarction, Risk, Hypertension, Risk assessment, MGH, Moyamoya disease, Patient, Hospital, Heart failure, Cardiovascular disease, Pharmaceutical industry, Medicine

Researchers from Massachusetts General Hospital (MGH) tested 241 patients with chronic total occlusion of at least one coronary (heart) artery for the risk of a major adverse cardiac event, including non-fatal myocardial infarction, stroke, and cardiovascular death through four years follow up.

Key Points: 
  • Researchers from Massachusetts General Hospital (MGH) tested 241 patients with chronic total occlusion of at least one coronary (heart) artery for the risk of a major adverse cardiac event, including non-fatal myocardial infarction, stroke, and cardiovascular death through four years follow up.
  • Using HART CVE risk scores, the high-risk patients were more than 12 times more likely to experience a myocardial infarction, stroke, or cardiovascular death as compared to low-risk patients.
  • Approximately 25% of patients with obstructive heart disease have Chronic Total Occlusion or total blockage of a coronary heart artery.
  • “HART CVE demonstrated robust accuracy for determining risk in these Chronic Total Occlusion patients.